CN1977852B - 含有二苯乙烯总苷的药物组合物及其在制备治疗乙型肝炎药物中的应用 - Google Patents
含有二苯乙烯总苷的药物组合物及其在制备治疗乙型肝炎药物中的应用 Download PDFInfo
- Publication number
- CN1977852B CN1977852B CN2005101276359A CN200510127635A CN1977852B CN 1977852 B CN1977852 B CN 1977852B CN 2005101276359 A CN2005101276359 A CN 2005101276359A CN 200510127635 A CN200510127635 A CN 200510127635A CN 1977852 B CN1977852 B CN 1977852B
- Authority
- CN
- China
- Prior art keywords
- total glycosides
- stilbene total
- preparation
- stilbene
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 title claims abstract description 97
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 5
- 229930182470 glycoside Natural products 0.000 title claims description 97
- 150000002338 glycosides Chemical class 0.000 title claims description 97
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 title claims description 96
- 235000021286 stilbenes Nutrition 0.000 title claims description 96
- 239000003814 drug Substances 0.000 claims abstract description 46
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 238000002347 injection Methods 0.000 claims abstract description 14
- 239000007924 injection Substances 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 24
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 19
- 230000001154 acute effect Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 206010067125 Liver injury Diseases 0.000 claims description 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 10
- 231100000012 chronic liver injury Toxicity 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 5
- 231100000439 acute liver injury Toxicity 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 10
- HSTZMXCBWJGKHG-UHFFFAOYSA-N (E)-piceid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(C=CC=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-UHFFFAOYSA-N 0.000 abstract description 2
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract description 2
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract description 2
- 229960003764 polydatin Drugs 0.000 abstract description 2
- HSTZMXCBWJGKHG-CUYWLFDKSA-N trans-piceid Polymers O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 HSTZMXCBWJGKHG-CUYWLFDKSA-N 0.000 abstract description 2
- 229930182478 glucoside Natural products 0.000 abstract 1
- 150000008131 glucosides Chemical class 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 21
- 241000272522 Anas Species 0.000 description 19
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 231100000753 hepatic injury Toxicity 0.000 description 12
- 241000272525 Anas platyrhynchos Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 231100001274 therapeutic index Toxicity 0.000 description 9
- 241000700721 Hepatitis B virus Species 0.000 description 8
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 101710142246 External core antigen Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 231100000234 hepatic damage Toxicity 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000008818 liver damage Effects 0.000 description 6
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002155 anti-virotic effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 238000003672 processing method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 241000725618 Duck hepatitis B virus Species 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 229960001627 lamivudine Drugs 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010059193 Acute hepatitis B Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 241000219050 Polygonaceae Species 0.000 description 2
- 241001648835 Polygonum cuspidatum Species 0.000 description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- -1 patch Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical compound C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101276359A CN1977852B (zh) | 2005-12-07 | 2005-12-07 | 含有二苯乙烯总苷的药物组合物及其在制备治疗乙型肝炎药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101276359A CN1977852B (zh) | 2005-12-07 | 2005-12-07 | 含有二苯乙烯总苷的药物组合物及其在制备治疗乙型肝炎药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1977852A CN1977852A (zh) | 2007-06-13 |
CN1977852B true CN1977852B (zh) | 2010-04-21 |
Family
ID=38129272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005101276359A Expired - Fee Related CN1977852B (zh) | 2005-12-07 | 2005-12-07 | 含有二苯乙烯总苷的药物组合物及其在制备治疗乙型肝炎药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1977852B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2468803C2 (ru) * | 2011-03-02 | 2012-12-10 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Применение полидатина для лечения заболеваний печени и фармацевтическая композиция на основе полидатина |
CN102675061B (zh) * | 2011-10-31 | 2016-01-20 | 合肥市济泉医药科技有限公司 | 白藜芦醇的醚衍生物和医疗用途 |
RU2505289C2 (ru) * | 2011-11-07 | 2014-01-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Фармацевтическая композиция на основе растительной докозагексаеновой кислоты для лечения и профилактики заболеваний печени |
CN103156827A (zh) * | 2011-12-09 | 2013-06-19 | 天津市国际生物医药联合研究院 | 二苯乙烯类化合物在治疗和预防艾滋病中的用途 |
CN112110966B (zh) * | 2020-10-14 | 2023-10-03 | 牛倩 | 白藜芦醇糖苷类衍生物、制备和用途 |
CN112057599A (zh) * | 2020-10-26 | 2020-12-11 | 北京沃德中医药研究院 | 一种治疗病毒性乙肝的中药药物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1460481A (zh) * | 2003-06-11 | 2003-12-10 | 陕西太明药物研究开发有限公司 | 以白藜芦醇苷为组成治疗脂肪肝的药物及其制备方法 |
CN1182149C (zh) * | 2003-01-27 | 2004-12-29 | 成都锦绣生物医药科技有限责任公司 | 以白藜芦醇甙为有效药物成分的保肝降脂药物 |
CN1194675C (zh) * | 2002-07-08 | 2005-03-30 | 中国人民解放军军事医学科学院放射医学研究所 | 反式3,4',5-三羟基二苯乙烯在制备治疗乙型肝炎病毒感染药物中的用途 |
-
2005
- 2005-12-07 CN CN2005101276359A patent/CN1977852B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1194675C (zh) * | 2002-07-08 | 2005-03-30 | 中国人民解放军军事医学科学院放射医学研究所 | 反式3,4',5-三羟基二苯乙烯在制备治疗乙型肝炎病毒感染药物中的用途 |
CN1182149C (zh) * | 2003-01-27 | 2004-12-29 | 成都锦绣生物医药科技有限责任公司 | 以白藜芦醇甙为有效药物成分的保肝降脂药物 |
CN1460481A (zh) * | 2003-06-11 | 2003-12-10 | 陕西太明药物研究开发有限公司 | 以白藜芦醇苷为组成治疗脂肪肝的药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1977852A (zh) | 2007-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100384467C (zh) | 一种治疗肝炎和脂肪肝的中药组合物 | |
CN1977852B (zh) | 含有二苯乙烯总苷的药物组合物及其在制备治疗乙型肝炎药物中的应用 | |
US9186385B2 (en) | Plant extract compositions for prevention and treatment of influenza | |
CN104523742B (zh) | 一种具有护肝和提高免疫作用的多糖组合物及其应用 | |
CN1069542C (zh) | 一种治疗慢性肝病的药物及其制备方法 | |
CN101186627B (zh) | 一种胡黄连苷i的制备方法 | |
CN100464755C (zh) | 具有免疫调节作用的抗化学性肝损伤的中药制剂 | |
CN101837004B (zh) | 薯蓣皂苷在制备肝保护药物制剂中的应用 | |
CN100482252C (zh) | 一种治疗乙肝的药物组合物 | |
CN1233388C (zh) | 治疗肝炎的药物组合物 | |
CN107485615A (zh) | 粗壮女贞苷c及其组合物在制备治疗高脂血症及减肥药物中的用途 | |
CN100386087C (zh) | 胡黄连苷i在制备治疗乙型肝炎药物中的应用 | |
CN1087617C (zh) | 一种治疗肝炎的胶囊 | |
CN106995479A (zh) | 化合物人参皂苷Rk1的制备方法及应用 | |
CN107753567B (zh) | 一种抗疲劳药物组合物及其制备方法及应用 | |
CN1795901B (zh) | 一种清热解毒、利湿退黄的药物 | |
CN1839931B (zh) | 一种治疗心脑血管疾病的药物组合物及其制备方法 | |
CN101057906B (zh) | 一种治疗肝炎的中药组合物及其药物制剂以及其应用 | |
CN103239569B (zh) | 蔓茎堇菜在制备治疗病毒性肝炎药物中的应用 | |
CN1319411A (zh) | 治疗慢性乙型肝炎的中药复方制剂及制备方法 | |
CN104258034A (zh) | 一种增强免疫力的中药组合物 | |
CN115737729B (zh) | 一种治疗骨质疏松的民族药制剂及其制备方法 | |
TWI654985B (zh) | 牛樟芝子實體複方酒萃物應用於製備b型肝炎治療用藥物的用途 | |
CN102008588B (zh) | 一种治疗肝性脑病和乙肝的药物组合物 | |
CN101194911A (zh) | 一种治疗乙型肝炎的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Yawei Document name: the First Notification of an Office Action |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU LVKAI GROWTH INVESTMENT CENTER (LIMITED PAR Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20150120 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100084 HAIDIAN, BEIJING TO: 215125 SUZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150120 Address after: 215125 No. 456, Pratt & Whitney Road, Suzhou Industrial Park, Jiangsu, China Patentee after: Suzhou green growth investment center (L.P.) Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100421 |
|
CF01 | Termination of patent right due to non-payment of annual fee |